PCT 1
Alternative Names: PCT-1Latest Information Update: 04 Aug 2024
Price :
$50 *
At a glance
- Originator Pan Cancer T
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Malignant melanoma; Triple negative breast cancer
Most Recent Events
- 11 Jul 2024 PCT 1 is available for licensing as of 11 Jul 2024. https://pancancer-t.com/pipeline/
- 11 Jul 2024 Preclinical trials in Malignant melanoma in Netherlands (Parenteral) prior to July 2024
- 11 Jul 2024 Preclinical trials in Triple-negative-breast-cancer in Netherlands (Parenteral) prior to July 2024